Focal Therapy Will Be the Future Treatment Modality: The Motion "Con"

European Urology, Supplements

Volumn 8, Issue 5, 2009, Pages 433-438

  Wehbi, Elias ^a   Musquera, Mireia ^b   Alcaraz, Antonio ^c   Hanna, Sally ^a,b   Fleshner, Neil E ^b   Zlotta, Alexandre R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Active surveillance; Cryotherapy; Focal therapies for prostate cancer; High intensity focused ultrasound; Photodynamic therapy; Prostate cancer; Radio frequency ablation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CRYOTHERAPY; DISEASE COURSE; FOCAL THERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MORBIDITY; MULTIPLE CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT MONITORING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; RADIOFREQUENCY ABLATION; RISK ASSESSMENT;

EID: 60049092329     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.01.006     Document Type: Article

References (38)

1. Eggener S.E., Scardino P.T., Carroll P.R., et al. International Task Force on Prostate Cancer and the Focal Lesion Paradigm. J Urol 178 (2007) 2260-2267
2. Makarov D.V., and Partin A.W. Focal therapy for prostate cancer. Rev Urol 10 (2008) 81-82
3. Zlotta A.R., Djavan B., Matos C., et al. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 81 (1998) 265-275
4. Bahn D.K., Silverman P., Lee Sr. F., et al. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 20 (2006) 688-692
5. Trachtenberg J., Weersink R.A., Davidson S.R., et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 102 (2008) 556-562
6. Damber J.E., and Aus G. Prostate cancer. Lancet 371 (2008) 1710-1721
7. Fleshner N.E., and Zlotta A.R. Prostate cancer prevention: past, present and future. Cancer 110 (2007) 1889-1899
8. Dall'era M.A., Cooperberg M.R., Chan J.M., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112 (2008) 1650-1659
9. Klotz L. Active surveillance for favorable risk prostate cancer: rationale, risks, and results. Urol Oncol 25 (2007) 505-509
10. Jeldres C., Suardi N., Walz J., et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol. 54 (2008) 1306-1313
11. Sengupta S., Blute M.L., Bagniewski S.M., et al. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int 101 (2008) 170-174
12. Van den Bergh R.C.N., Roemeling S., Roobol M.J., et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55 (2009) 1-8
13. Klotz L. Active surveillance for prostate cancer: trials and tribulations. World J Urol 26 (2008) 437-442
14. Donovan J.L., Lane J.A., Peters T.J., et al., ProtecT Study Group. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol 62 (2009) 29-36
15. Noguchi M., Stamey T.A., McNeal J.E., et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170 (2003) 459-463
16. Song S.Y., Kim S.R., Ahn G., et al. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients. Prostate Cancer Prostatic Dis 6 (2003) 143-147
17. Ng J.C., Koch M.O., Daggy J.K., et al. Perineural invasion in radical prostatectomy specimens: lack of prognostic significance. J Urol 172 (2004) 2249-2251
18. Eichelberger L.E., and Cheng L. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 100 (2004) 2573-2576
19. Scales Jr. C.D., Presti Jr. J.C., Kane C.J., et al. J Urol 178 (2007) 1249-1252
20. Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology. In press.
21. Mouraviev V., Mayes J.M., Sun L., Madden J.F., Moul J.W., and Polascik T.J. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110 (2007) 906-910
22. Meiers I., Waters D.J., and Bostwick D.G. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology 70 Suppl 6 (2007) 3-8
23. Haffner J, Potiron E, Bouyé S, et al. Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. Prostate. In press. doi:10.1002/pros.20881.
24. Polascik T.J., Mayes J.M., Sun L., Madden J.F., Moul J.W., and Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 68 (2008) 1380-1386
25. Onik G., and Barzell W. Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 26 (2008) 506-510
26. Ogura K., Maekawa S., Okubo K., et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology 57 (2001) 721-726
27. Preziosi P., Orlacchio A., Di Giambattista G., et al. Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol 13 (2003) 925-930
28. Schlemmer H.P., Merkle J., Grobholz R., et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?. Eur Radiol 14 (2004) 309-317
29. Nakashima J., Tanimoto A., Imai Y., et al. Endorectal MRI for prediction of tumour site, tumour size, and local extension of prostate cancer. Urology 64 (2004) 101-105
30. Haider M.A., van der Kwast T.H., Tanguay J., et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 189 (2007) 323-328
31. Kirkham A.P.S., Emberton M., and Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 50 (2006) 1163-1175
32. Langer D.L., van der Kwast T.H., Evans A.J., et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 249 (2008) 900-908
33. Cresswell J., Asterling S., Chaudhary M., Sheikh N., and Greene D. Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. BJU Int 97 (2006) 969-974
34. Bahn D.K., Lee F., Badalament R., Kumar A., Greski J., and Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60 Suppl 2 (2002) 3-11
35. Blana A., Rogenhofer S., Ganzer R., et al. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 72 (2008) 1329-1333
36. Pinthus J., Bogaards A., Weersink R., Wilson B., and Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol 175 (2006) 1201-1207
37. Nathan T., Whitelaw D., Chang S., Lees W., Ripley P., and Payne H. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 168 (2002) 1427-1432
38. Shariat S., Raptidis G., Masatoschi M., Bergamaschi F., and Slawin K. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 65 (2005) 260-267